Takeda: Osteoporosis trials

The registry lists 13 Osteoporosis studies with Takeda as lead sponsor. 0 are open to participants now and 6 have results posted.

Phase 2 2Phase 3 6Phase 4 3No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• 36-month Special Drug Use Surveillance on Frequency of Bone Fractures With Sodium Risedronate 75 mg TabletsCompletedNCT02106442Results posted
• Special Drug Use Surveillance on Long-term Use of Sodium Risedronate Tablets (Benet 75 mg Tablets) (12-month Treatment Survey)CompletedNCT02089997Results posted
• A Phase II/III, Double-blind, Parallel Group Comparative Study of Oral Administration of NE-58095 TabletsCompletedNCT02063854Phase 2/3Results posted
• The Effect of PTH(1-84) or Alendronate on Reduction of Back Pain in Postmenopausal Women With an Osteoporosis Related Vertebral Fracture(s) (FP-005-IM)TerminatedNCT00713258Phase 4Results posted
• Effect of Full Length Parathyroid Hormone, PTH(1-84) or Strontium Ranelate on Bone Markers in Postmenopausal Women With Primary Osteoporosis (FP-006-IM)CompletedNCT00479037Phase 4Results posted
• Sequential Treatment of Postmenopausal Women With Primary Osteoporosis (FP-001-IM)CompletedNCT00365456Phase 3Results posted
• STEP: Study of Imaging Techniques (ImaTx and DXA) in Postmenopausal Women With OstEoporosis Using Preotact (FP-008-ES)CompletedNCT00583518Phase 4
• PROPOSE Quality - PReOtact in Postmenopausal OStEoporosis - Quality of Life Study (FP-004-DE)CompletedNCT00515593
• Calcium Supplementation in Postmenopausal WomenCompletedNCT00172172Phase 3
• Open Label Extension Study of PREOSCompletedNCT00172133Phase 3
• Open Label ExtensionCompletedNCT00172120Phase 3
• A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal OsteoporosisCompletedNCT00172107Phase 2
• TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal OsteoporosisCompletedNCT00172081Phase 3